Group 1 - Medtronic's MiniMed Group is targeting to raise up to $784 million in its initial public offering (IPO) in the United States [1] - The IPO is part of Medtronic's strategy to enhance its diabetes business and expand its market presence [1]

Group 1: FedEx and IEEPA Tariffs - FedEx has filed a lawsuit against the Trump administration seeking a full refund of tariffs paid under the International Emergency Economic Powers Act (IEEPA) following a Supreme Court ruling against the administration [3] - The lawsuit does not specify the amount due and names the Customs and Border Protection agency and its commissioner as defendants [3] - Other companies, including Costco, have also filed similar lawsuits, with economists projecting that reversing the IEEPA tariffs could generate up to $175 billion in refunds [4] Group 2: Hims & Hers Health - Hims & Hers Health disclosed an SEC investigation regarding its public statements and disclosures about compounded semaglutide, stating it is cooperating but cannot predict the financial impact [5][6] - The company reported Q4 GAAP EPS of $0.08, beating estimates by $0.03, with revenue rising 28.4% year-over-year to $617.8 million, in line with expectations [6] - Subscriber growth reached over 2.5 million, a 13% increase year-over-year, but the company guided for Q1 2026 revenue between $600 million and $625 million, below the consensus estimate of $652.6 million [6] Group 3: IBM and AI Claims - IBM's shares experienced their worst decline in over 25 years after AI startup Anthropic claimed its tool could modernize COBOL, a programming language used on IBM systems [7][8] - The stock fell over 13%, marking its largest single-day percentage loss since October 2000, and has dropped 27% in February, on track for its biggest monthly decline since at least 1968 [8]

Core Viewpoint - AstraZeneca CEO Pascal Soriot's pay for 2025 has increased by 6.4% to approximately $24 million, primarily due to higher annual bonuses, maintaining his position among the highest-paid executives in the FTSE 100 [1]. Group 1: CEO Compensation - Pascal Soriot's total pay for 2025 is reported at 17.7 million pounds ($23.87 million) [1]. - The annual bonus for Soriot reached 4.3 million pounds, reflecting a 22% increase from the previous year [1]. Group 2: Company Performance - AstraZeneca is noted as London's most valuable company, with a significant increase in earnings reported for 2025 [1].

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. Dive Brief: AbbVie announced it will spend $380 million to build two new U.S. facilities at its existing campus in North Chicago, Illinois that will integrate advanced manufacturing technologies with artificial intelligence to produce next-generation neuroscience and obesity drugs. Construction will begin in spring of 2026, with the plants scheduled ...

Amphastar Announces FDA Approval for Ipratropium Bromide HFA ELEMENT--[Back to the Newsroom]# Amphastar Announces FDA Approval for Ipratropium Bromide HFARANCHO CUCAMONGA, CA / [ACCESS Newswire]/ February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation. The FDA determined that Amphastar's Ipratropium Bromide ...

Core Insights - The past year has been challenging for Japanese pharmaceutical company Daiichi Sankyo, marked by earnings misses and concerns regarding clinical efficacy and safety [1] Financial Performance - Daiichi Sankyo has experienced earnings misses, indicating potential issues in financial performance and market expectations [1] Clinical Concerns - There are growing worries about the clinical efficacy and safety of Daiichi Sankyo's products, which could impact investor confidence and market position [1]

长春高新公告，子公司金赛药业收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金 赛药业GenSci141软膏境内生产药品注册临床试验申请获得批准。GenSci141软膏是金赛药业研发的一款 双氢睾酮软膏，属于化学药品2.2类、2.4类。 ...

Group 1 - The core point of the article is that Novo Nordisk's experimental obesity drug, developed in collaboration with China's United Laboratories International Holdings, has shown effectiveness in aiding weight loss during a midstage clinical trial conducted in China [1]

Core Insights - Novo Nordisk's triple agonist UBT251 achieved a statistically significant mean weight loss of up to 19.7% after 24 weeks in a trial conducted in China [1][2] - The trial compared three doses of UBT251 (2 mg, 4 mg, and 6 mg) against a placebo in individuals with overweight or obesity [1] Group 1 - The baseline mean body weight of participants was 92.2 kilograms, with the highest mean weight loss observed in the UBT251 group being 19.7%, compared to only 2.0% in the placebo group after 24 weeks [2]

Investment Plans - AbbVie has announced a $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities in North Chicago, Illinois, integrating advanced manufacturing technologies and AI for obesity and next-generation neuroscience medications [1][2] - Construction is set to begin in spring 2026, with both facilities expected to be operational by 2029 [1] Employment and Capacity Expansion - The company plans to hire 300 employees in North Chicago, including manufacturing operators, scientists, lab technicians, and engineers to support the expanded operations [2] - AbbVie has been increasing its API manufacturing capacity in the US over the past six months [2] Relocation of Production - In September 2025, AbbVie initiated the first phase of this investment by breaking ground on a chemical synthesis facility aimed at relocating API production for certain neuroscience, immunology, and oncology products from Europe and Asia back to the US [3] Additional Investments - AbbVie has also revealed plans for a device manufacturing facility acquisition in Arizona and significant investments at its Massachusetts site, with further investments in other US states expected to be announced in 2026 [4] - The chairman and CEO stated that this milestone reflects progress towards a $100 billion commitment to US R&D and capital investments over the next decade [4] Strategic Acquisitions - In August 2025, AbbVie signed an agreement to acquire Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, for up to $1.2 billion, which includes upfront payments and development milestones [5]